cannabis community care

Cannabis Community Care & Research Network (C3RN) Partners with HNF

by | Oct 11, 2018 | 0 comments

Cannabis Community Care & Research Network (C3RN) is excited to be partnering with the Hereditary Neuropathy Foundation (HNF) to advance Cannabis research, advocate for patients in need, and educate the community!

C3RN’s team is passionate about ending stigma and advancing Cannabis research. The team is made up of Dr’s, Scientists, Growers, Creators, and Doer’s…but most importantly they are medical patients who understand the importance of education and awareness. There are so many ways that this plant can help people with their ailments, but how do we know? Stigma ends where education and awareness begins and whether it is via survey, verbal testimony, or social media…sharing your story is the start. Director of Sales; Andy Westerkamp shares his patient story on their websiteAndy is living with HNPP and manages to improve his quality of life with the help of Cannabis.

Take a look at some of the national statistics from an ongoing IRB approved anonymous patient and consumer survey from C3RN and UMass Dartmouth:

  • 62% of Cannabis users are reducing prescription medication use.
  • 51% report using Cannabis to ease anxiety.
  • 46% use Cannabis to manage chronic pain.

HNF, in partnership with Champlain Valley Dispensary/Ceres, is conducting a medical cannabis survey for CMT/HNPP patients to determine if its use is beneficial. Questions concerning types, amounts, methods of consumption and utilization of prescription drugs will help inform researchers. Please find the survey below. This study is generously supported by Champlain / Ceres.

champlain valley dispensaryceres logo 2

Learn more on this topic

Related Blog Posts

The Long Road to Diagnosis Renews Dedication to Advocacy

The Long Road to Diagnosis Renews Dedication to Advocacy

Growing up we called it “Steffi disorder.” My friends and family were as baffled as my expert neurologists. I had been diagnosed with typical Spiral Muscular Atrophy (SMA) as a toddler but never followed its progression; I never seemed to get weaker. My myriad of symptoms was distinctly different than anyone else’s I had ever met in a lifetime living in the neuromuscular community. I thought I might never find my true diagnosis, let alone others who share it with me.

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news